Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:
Karim Fizazi, MD, PhD
Institut Gustave Roussey
Joaquin Mateo, MD, PhD
Vall d’Hebron University Hospital,
Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)
Downloadable slideset from Eric Jonasch, MD on managing treatment-related adverse events for patients with RCC, from Clinical Care Options (CCO).
Downloadable slideset from Katy E. Beckermann, MD, PhD on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy, from Clinical Care Options (CCO).
Downloadable slideset from Naomi B. Haas, MD on adjuvant approaches and first line treatment options for patients with RCC, from Clinical Care Options (CCO).